NCT03956862CompletedPhase 2
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.36 sites in 3 countries97 target enrollmentStarted: May 16, 2019Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 97
- Locations
- 36
- Primary Endpoint
- Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score
Study Overview
Brief Summary
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients with chronic rhinosinusitis with or without nasal polyposis (NP).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic rhinosinusitis without nasal polyps (CRSsNP) by a physician at least 12 weeks before Screening Visit
- •Treated with stable intranasal corticosteroid (INCS) for at least 2 months prior to Screening Visit
- •Presence of at least 2 nasal symptoms: nasal blockage/ obstruction/congestion or nasal discharge or facial pain/pressure or reduction/loss of smell
- •Women of childbearing potential must use an acceptable method of contraception
Exclusion Criteria
- •Sino-Nasal Outcome Test-22 (SNOT-22) score < 20 at screening
- •Asthma or chronic obstructive pulmonary disease (COPD) patients that are current smokers
- •Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit
- •Pregnant or breastfeeding
- •Pre-existing clinically important co-morbidities
- •Regular use of systemic corticosteroids or immunosuppressive treatments
- •Other protocol-defined inclusion/exclusion criteria will apply.
Arms & Interventions
GB001
Experimental
GB001 40 mg once per day (QD) for 16 weeks
Intervention: GB001 (Drug)
Placebo
Placebo Comparator
Placebo QD for 16 weeks
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score
Time Frame: Baseline, Week 16
The SNOT-22 is a validated questionnaire to assess the impact of chronic rhinosinusitis (CRS) on quality of life and utilizes a 2-week recall period. It is a 22-item outcome measure on a 5-point category scale applicable to sinonasal conditions and surgical treatments. The total scores range from 0 to 110 with higher total scores implying greater impact of CRS on quality of life.
Secondary Outcomes
- Change From Baseline to Week 16 in Lund-Mackay Score(Baseline, Week 16)
- Time to First Response in NPS(up to Week 16)
- Time to First Chronic Rhinosinusitis (CRS) Exacerbation(up to Week 16)
- Change From Baseline to Week 16 in AM Total Symptom Score (TSS)(Baseline, Week 16)
- Change From Baseline to Week 16 in University of Pennsylvania Smell Identification Test (UPSIT) Score(Baseline, Week 16)
- Percentage of Participants With a Treatment-Emergent Adverse Event (AE)(From first dose of study drug through Week 20)
- Change From Baseline to Week 16 in Morning (AM) Nasal Congestion (NC) Score(Baseline, Week 16)
- Change From Baseline to Week 16 in Nasal Polyp Score (NPS)(Baseline, Week 16)
Investigators
Study Sites (36)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).Intestinal Failure Associated Liver DiseaseNCT05919680NorthSea Therapeutics B.V.36
Withdrawn
Phase 2
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B SubjectsHepatitis B, ChronicNCT03125213Alios Biopharma Inc.
Completed
Phase 2
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney DiseaseChronic Kidney DiseasesHypertensionNCT03574363KBP Biosciences162
Withdrawn
Phase 2
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung CancerCarcinoma, Non-Small Cell LungNCT04611776Hoffmann-La Roche
Terminated
Phase 2
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based TherapyUrothelial CarcinomaNCT03029832Genentech, Inc.5